1. Home
  2. GLUE vs ARI Comparison

GLUE vs ARI Comparison

Compare GLUE & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$23.69

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Apollo Commercial Real Estate Finance Inc

ARI

Apollo Commercial Real Estate Finance Inc

HOLD

Current Price

$10.19

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLUE
ARI
Founded
2019
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
GLUE
ARI
Price
$23.69
$10.19
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
$32.00
$11.00
AVG Volume (30 Days)
1.5M
3.4M
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
9.31%
EPS Growth
N/A
183.51
EPS
N/A
0.16
Revenue
$123,672,000.00
$271,589,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.45
N/A
P/E Ratio
$72.42
$63.94
Revenue Growth
63.54
N/A
52 Week Low
$4.12
$9.49
52 Week High
$25.77
$11.24

Technical Indicators

Market Signals
Indicator
GLUE
ARI
Relative Strength Index (RSI) 66.28 32.58
Support Level $17.35 $10.18
Resistance Level $25.56 $10.35
Average True Range (ATR) 1.57 0.19
MACD 0.37 -0.06
Stochastic Oscillator 78.81 0.00

Price Performance

Historical Comparison
GLUE
ARI

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

About ARI Apollo Commercial Real Estate Finance Inc

Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.

Share on Social Networks: